Your shopping cart is currently empty

AF-45 inhibits IRAK4 and IRAK1 with IC50 values of 128 nM and 1765 nM, respectively. It suppresses the release of IL-6 and TNF-α in macrophages, with IC50 ranges of 0.53-1.54 μM and 0.6-2.75 μM, respectively. Additionally, AF-45 acts as an inhibitor of the NF-κB/MAPK signaling pathway. In mouse models, AF-45 exhibits anti-inflammatory activity against DSS-induced ulcerative colitis and lipopolysaccharide-induced acute lung injury. In rat models, AF-45 demonstrates favorable pharmacokinetic properties.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | AF-45 inhibits IRAK4 and IRAK1 with IC50 values of 128 nM and 1765 nM, respectively. It suppresses the release of IL-6 and TNF-α in macrophages, with IC50 ranges of 0.53-1.54 μM and 0.6-2.75 μM, respectively. Additionally, AF-45 acts as an inhibitor of the NF-κB/MAPK signaling pathway. In mouse models, AF-45 exhibits anti-inflammatory activity against DSS-induced ulcerative colitis and lipopolysaccharide-induced acute lung injury. In rat models, AF-45 demonstrates favorable pharmacokinetic properties. |
| Targets&IC50 | IRAK4:128 nM, IRAK1:1765 nM |
| Formula | C22H25N3O3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.